Ongoing Clinical Trial

Ongoing Clinical Trial

1. A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum Based Chemotherapy and Metastatic Breast Cancer with Germline BRCA1/2 Mutation (SOLI Study).

2. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Compare NSAI plus Abemaciclib, a CDK4 and CDK6 Inhibitor, or plus Placebo and to Compare Fulvestrant plus Abemaciclib or plus Placebo in Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer(I3Y-CR-JPBQ )

3. A Randomized, Open-Label, Phase 3 Study of Abemaciclib combined with Standard Adjuvant Endocrine Therapy versus Standard Adjuvant Endocrine Therapy Alone in Patients with High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative Breast Cancer (monarchE).( I3Y-MC-JPCF )

4. A Randomized, Double-blind, Parallel Group, Equivalence, Multicentre Phase III Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in patients with Metastatic or Recurrent Non-squamous Non-small Cell Lung Cancer.( SAMSON-II)

5. A Prospective, Randomized, Open-Label, Comparative, Multicentric Phase III Clinical Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Diltiazem Hydrochloride 2% w/w and Lidocaine 2% w/w Gel against Diltiazem Hydrochloride 2% w/w Gel in the Treatment of Anal Fissure.( DILI3001 )

6. A randomized, double-blind, parallel group, Phase III trial to compare the efficacy, safety, and immunogenicity of TX05 with Herceptin® in subjects with HER2 positive early breast cancer. ( TX0503)

7. A double-blinded extension study to provide adjuvant treatment with single agent Herceptin® or TX05 and assess continued safety and immunogenicity in subjects with HER2-positive early breast cancer following neoadjuvant treatment and surgical resection in Protocol TX05-03. ( TX0503E )

8. A phase II randomized study of the combination of Ribociclib plus goserelin acetate with Hormonal Therapy versus physician choice chemotherapy in premenopausal or perimenopausal patients with hormone receptor positive/ HER2-negative inoperable locally advanced or metastatic breast cancer (RIGHT Choice Study)

9. A descriptive study of PIK3CA mutations in patients with HR+/Her2- advanced breast cancer (PIK3CA Registry Study).

10. A Randomized, Open Label 2-Treatment Group Clinical Trial Evaluating the Efficacy and Safety of 2-Deoxy-D-Glucose as an adjunctive therapy to standard of care, in comparison to standard of care alone, in the Acute treatment of Moderate to Severe COVID-19 patients(CVD-02-CD-002 )

11. A prospective, open-label, multicentre, randomized, non-inferiority clinical trial to compare the safety and performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System versus Contemporary DES platforms in patients with de novo coronary artery lesions.(MeRethon RCT)

12. Ultra-Thin strUt versus XiencE in a Diabetic pOpulation with Multi-Vessel Disease– 2– India Study. ( TUXEDO-2)

13. A prospective, post-marketing, multi-center, study to evaluate safety and performance of the Evermine 50- Everolimus Eluting Coronary Stent System (EES) in the treatment of patients with de novo coronary artery lesions.( Evermine 50 EES)

14. A Phase III, Multicenter, Multi-country, Open-label, Randomized, Active-controlled clinical trial to evaluate the efficacy and safety of Desidustat versus Darbepoetin for the treatment of anemia in patients with chronic kidney disease (CKD) who are not on dialysis.(DESI.18.001)

15. A post market registry of albuminus sirolimus eluting coronary stent system for percutaneous intervention in patients with Diabetes Mellitus (DEDICATE Registry)

16. A phase III, randomized, multi-centre, double blind, placebo controlled, study to evaluate efficacy, safety and immunogenicity of Novel Corona Virus -2019-nCov vaccine candidate of M/s Cadila Healthcare Limited.(NCOV.20.002 )